RESPONSE-ADAPTED TREATMENT WITH RITUXIMAB/BENDAMUSTINE/MITOXANTRONE/DEXAMETHASONE AND MAINTENANCE THERAPY WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA IN RELAPSE OR REFRACTORY TO FIRST-LINE TREATMENT WITH IMMUNOCHEMOTHERAPY. RBMDGELTAMO08

被引：0

作者：

Francisco Javier, Penalver Parraga ^{[1
]}

Jose Antonio, Marquez Navarro ^{[2
]}

Nieto Soledad, Duran ^{[3
]}

Castellano Pilar, Giraldo ^{[4
]}

Sanz Carlos, Montalban ^{[5
]}

Maria Jose, Ramirez Sanchez ^{[6
]}

Juan Manuel, Sancho Cia ^{[7
]}

Maria Jose, Terol Castera ^{[8
]}

Francisco Javier, Capote Huelva ^{[9
]}

Garcia Antonio, Gutierrez ^{[10
]}

Gonzalez Blanca, Sanchez ^{[11
]}

Silvestre Antonio, Salar ^{[11
]}

Albendea Miguel, Canales ^{[12
]}

Maria Dolores, Caballero Barrigon

机构：

[1] Hosp Univ Fdn Alcorcon, Madrid, Spain

[2] Hosp Basurto, Bilbao, Spain

[3] Complejo Hosp Jaen, Jaen, Spain

[4] Hosp Univ Miguel Servet, Zaragoza, Spain

[5] Hosp Univ Ramon & Cajal, Madrid, Spain

[6] Hosp Especialidades Jerez de la Frontera, Cadiz, Spain

[7] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[8] Hosp Clin Univ Valencia, Valencia, Spain

[9] Hosp Puerta del Mar, Cadiz, Spain

[10] Hosp Univ Son Dureta, Palma De Mallorca, Spain

[11] Hosp del Mar, Barcelona, Spain

[12] Hosp Univ La Paz, Madrid, Spain

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CO-011

引用

页码：9 / 9

页数：1

共 50 条

[21] SAFETY AND EFFICACY OF RITUXIMAB AND CHLORAMBUCIL IN COMBINATION AS FIRST-LINE TREATMENT IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS
Martinelli, G.
Andreola, G.
Laszlo, D.
Minga, P.
Cannella, L.
Liptrott, S.
Sammassimo, S.
Linetti, M.
Calabrese, L.
Bassi, S.
HAEMATOLOGICA, 2012, 97 : 651 - 652
[22] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis
Pouyiourou, M.
Meyer, A.
Stroux, A.
Viardot, A.
La Rosee, P.
Maschmeyer, G.
Kaempfe, D.
Kahl, C.
Vucinic, V.
Monecke, A.
Hirt, C.
Weber, T.
Meissner, J.
Witzens-Harig, M.
Boettcher, S.
Schmalenberg, H.
Marks, R.
Prange-Krex, G.
Kroschinsky, F.
Hauf, E.
Keller, U.
Koch, K.
Klapper, W.
Herold, M.
Scholz, Christian W.
ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2821 - 2829
[23] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis
M. Pouyiourou
A. Meyer
A. Stroux
A. Viardot
P. La Rosée
G. Maschmeyer
D. Kämpfe
C. Kahl
V. Vucinic
A. Monecke
C. Hirt
T. Weber
J. Meissner
M. Witzens-Harig
S. Böttcher
H. Schmalenberg
R. Marks
G. Prange-Krex
F. Kroschinsky
E. Hauf
U. Keller
K. Koch
W. Klapper
M. Herold
Christian W. Scholz
Annals of Hematology, 2020, 99 : 2821 - 2829
[24] COST-EFFECTIVENESS ANALYSIS OF MAINTENANCE TREATMENT WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA RESPONDING TO FIRST LINE INDUCTION THERAPY IN PORTUGAL
Pereira, C.
Rubio Terres, C.
Rubio Rodriguez, D.
VALUE IN HEALTH, 2014, 17 (07) : A530 - A531
[25] First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial
Salar, Antonio
Domingo-Domenech, Eva
Panizo, Carlos
Nicolas, Concepcion
Bargay, Joan
Muntanola, Ana
Canales, Miguel
Luis Bello, Jose
Manuel Sancho, Juan
Francisco Tomas, Jose
Jose Rodriguez, Maria
Javier Penalver, Francisco
Grande, Carlos
Javier Sanchez-Blanco, Jose
Palomera, Luis
Arranz, Reyes
Conde, Eulogio
Garcia, Mar
Fernando Garcia, Juan
Caballero, Dolores
Montalban, Carlos
LANCET HAEMATOLOGY, 2014, 1 (03): : E104 - E111
[26] Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma A NICE Single Technology Appraisal
Greenhalgh, Janette
Bagust, Adrian
Boland, Angela
Blundell, Michaela
Oyee, James
Beale, Sophie
Dundar, Yenal
Hockenhull, Juliet
Proudlove, Chris
Chu, Patrick
PHARMACOECONOMICS, 2013, 31 (05) : 403 - 413
[27] Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy
Hornberger, John
Chien, Rebecca
Friedmann, Mark
Han, Leona
Shewade, Ashwini
Satram-Hoang, Sacha
Reyes, Carolina
LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2371 - 2377
[28] Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study
Pott, Christiane
Hoster, Eva
Kehden, Britta
Unterhalt, Michael
Herold, Michael
van der Jagt, Richard H.
Janssens, Ann
Kneba, Michael
Mayer, Jiri
Pocock, Chris
Danesi, Nathalie
Fingerle-Rowson, Gunter
Harbron, Chris
Mundt, Kirsten
Marcus, Robert E.
Hiddemann, Wolfgang
BLOOD, 2016, 128 (22)
[29] Rituximab maintenance after R-CHOP in the first-line treatment of follicular lymphoma: A GOTEL phase II trial
Rueda, A.
Provencio, M.
Abrio, M.
Gomez-Codina, J.
Llanos, M.
Delgado, J.
Rifa, J.
Sabin, P.
Velez de Mendizabal, E.
Baz, V.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[30] The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study
Galimberti, Sara
Ciabatti, Elena
Ercolano, Giacomo
Grassi, Susanna
Guerrini, Francesca
Cecconi, Nadia
Rousseau, Martina
Cervetti, Guilia
Mazziotta, Francesco
Iovino, Lorenzo
Falzetti, Franca
Falcinelli, Flavio
Bosi, Alberto
Rigacci, Luigi
Kovalchuk, Sofia
Vallisa, Daniele
Macchia, Lucia
Ciancia, Eugenio
Petrini, Mario
FRONTIERS IN PHARMACOLOGY, 2017, 8

← 1 2 3 4 5 →